Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

188 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B.
Papatheodoridis GV, Idilman R, Dalekos GN, Buti M, Chi H, van Boemmel F, Calleja JL, Sypsa V, Goulis J, Manolakopoulos S, Loglio A, Siakavellas S, Keskın O, Gatselis N, Hansen BE, Lehretz M, de la Revilla J, Savvidou S, Kourikou A, Vlachogiannakos I, Galanis K, Yurdaydin C, Berg T, Colombo M, Esteban R, Janssen HLA, Lampertico P. Papatheodoridis GV, et al. Among authors: yurdaydin c. Hepatology. 2017 Nov;66(5):1444-1453. doi: 10.1002/hep.29320. Epub 2017 Oct 11. Hepatology. 2017. PMID: 28622419
Risk factors for hepatocellular carcinoma in Turkey.
Uzunalimoğlu O, Yurdaydin C, Cetinkaya H, Bozkaya H, Sahin T, Colakoğlu S, Tankurt E, Sarioğlu M, Ozenirler S, Akkiz H, Tözün N, Değertekin H, Okten A. Uzunalimoğlu O, et al. Among authors: yurdaydin c. Dig Dis Sci. 2001 May;46(5):1022-8. doi: 10.1023/a:1010705910858. Dig Dis Sci. 2001. PMID: 11341644
Famciclovir treatment of chronic delta hepatitis.
Yurdaydin C, Bozkaya H, Gürel S, Tillmann HL, Aslan N, Okçu-Heper A, Erden E, Yalçin K, Iliman N, Uzunalimoglu O, Manns MP, Bozdayi AM. Yurdaydin C, et al. J Hepatol. 2002 Aug;37(2):266-71. doi: 10.1016/s0168-8278(02)00162-9. J Hepatol. 2002. PMID: 12127433 Clinical Trial.
Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks.
Sherman M, Yurdaydin C, Simsek H, Silva M, Liaw YF, Rustgi VK, Sette H, Tsai N, Tenney DJ, Vaughan J, Kreter B, Hindes R; AI463026 Benefits of Entecavir for Hepatitis B Liver Disease (BEHoLD) Study Group. Sherman M, et al. Among authors: yurdaydin c. Hepatology. 2008 Jul;48(1):99-108. doi: 10.1002/hep.22323. Hepatology. 2008. PMID: 18537189 Clinical Trial.
PPAR-alpha L162V polymorphism in human hepatocellular carcinoma.
Koytak ES, Mizrak D, Bektaş M, Verdi H, Arslan Ergül A, Idilman R, Cinar K, Yurdaydin C, Ersõz S, Karayalçin K, Uzunalimoğlu O, Bozkaya H. Koytak ES, et al. Among authors: yurdaydin c. Turk J Gastroenterol. 2008 Dec;19(4):245-9. Turk J Gastroenterol. 2008. PMID: 19119483 Free article.
188 results